Sources | Names Used |
---|---|
CTRPv2 | navitoclax:gemcitabine (1:1 mol/mol) |
PharmacoGx | navitoclax:gemcitabine (1:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CBX5 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
mRNA | DOT1L | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-07 |
mRNA | CD151 | CTRPv2 | pan-cancer | AAC | -0.21 | 4e-07 |
mRNA | SLC39A13 | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-07 |
mRNA | ESPL1 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
mRNA | SYNCRIP | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-07 |
mRNA | TMED7-TICAM2 | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-07 |
mRNA | ANP32A | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-07 |
mRNA | CTD-2369P2.12 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-07 |
mRNA | ARHGAP19 | CTRPv2 | pan-cancer | AAC | 0.21 | 5e-07 |